All In Biotech

Drug Trial Radar · NCT00094458

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE� (Infliximab) and REMICADE Plus Azathioprine to Azathioprine in the Treatment of Patients With Crohn's Disease Naive to Both Immunomodulators and Biologic Therapy

Last checked: Nov 20, 2026Latest source record: Feb 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 508 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

508

Actual

Start

Mar 2005

Primary completion

Apr 2008

Study completion Dec 2009

Sponsor

Lead sponsor
Centocor Ortho Biotech Services, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Schering-Plough
First posted
Oct 20, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 21 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and effectiveness of three different treatments for patients with Crohns disease who have not responded to previous treatment with a group of drugs commonly used to treat Crohn's Disease (5-ASA) and corticosteroids. Patients will receive either infliximab (a drug used to treat autoimmune diseases) or azathioprine (an immunosuppressant or drug used to suppress the immune system) or a combination of both for up to 34 weeks. This research study will involve approximately 500 patients. The main study involves up to 34 weeks (approximately 8 months). A study extension of an additional 20 weeks (approximately 5 months) is optional for patients who successfully complete the main study. A country-specific study extension of open label infliximab treatment for an additional 1 year is optional for patients who successfully complete the main study extension.

Conditions

  • Crohn Disease

Interventions

  • infliximab infusion; AZA placebo capsBiological

    Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules

  • infliximab (IFX) infusion; azathioprine (AZA) capsOther

    AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22

  • infliximab (IFX) placebo infusion; azathioprine (AZA) capsDrug

    AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Corticosteriod-free Clinical RemissionTime frame: Week 26

Locations

115 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Orange, California

  • Site not named

    Roseville, California

  • Site not named

    San Diego, California

  • Site not named

    San Luis Obispo, California

  • Site not named

    Golden, Colorado

  • Site not named

    Littleton, Colorado

  • Site not named

    Hartford, Connecticut

  • Site not named

    Gainesville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    North Miami Beach, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Austell, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Peoria, Illinois

  • Site not named

    Clive, Iowa

  • Site not named

    Overland Park, Kansas

  • Site not named

    Topeka, Kansas

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    Metairie, Louisiana

  • Site not named

    Troy, Michigan

  • Site not named

    Plymouth, Minnesota

  • Site not named

    Rochester, Minnesota

  • Site not named

    Ocean Springs, Mississippi

  • Site not named

    Tupelo, Mississippi

  • Site not named

    St Louis, Missouri

  • Site not named

    Urbana, Missouri

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Egg Harbor, New Jersey

  • Site not named

    Great Neck, New York

  • Site not named

    New Hyde Park, New York

  • Site not named

    New York, New York

  • Site not named

    Asheville, North Carolina

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Wilmington, North Carolina

  • Site not named

    Bend, Oregon

  • Site not named

    Portland, Oregon

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.